Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 478-484

  Tolcher, Anthony W ^a   Sugarman, Steven ^a   Gelmon, Karen A ^a   Cohen, Roger ^a   Saleh, Mansoor ^a   Isaacs, Claudine ^a   Young, Leslie ^a   Healey, Diane ^a   Onetto, Nicole ^a   Slichenmyer, William ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BMS 182248 1; DOXORUBICIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD GROUP LEWIS SYSTEM; BLOOD TOXICITY; BONE PAIN; BREAST CANCER; BREAST METASTASIS; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG RESPONSE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEMATEMESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; WHEEZING;

EID: 0032975042     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.478     Document Type: Article

References (11)

1. Trail PA, Willner D, Lasch SJ, et al: Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates [published erratum appears in Science 263:1076, 1994]. Science 261:212-215, 1993
2. Garrigues J, Garrigues U, Hellstrom I, et al: Ley specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes. Am J Pathol 142:607-622, 1993
3. Hellstrom I, Garrigues HJ, Garrigues U, et al: Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(Y)-related cell surface antigens. Cancer Res 50:2183-2190, 1990
4. Sjogren HO, Isaksson M, Willner D, et al: Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res 57:4530-4536, 1997
5. Comereski CR, Peden WM, Davidson TJ, et al: BR96-doxorubicin conjugate (BMS-182248) versus doxorubicin: A comparative toxicity assessment in rats. Toxicol Pathol 22:473-488, 1994
6. Saleh M, LoBuglio A, Sugarman S, et al: Gastrointestinal effects of chimeric BR96-doxorubicin (DOX) conjugate. Proc Am Assoc Cancer Res 36:A2876, 1995 (abstr)
7. Sugarman S, Murray JL, Saleh M, et al: A phase I study of BR96-doxorubicin (BR96-Dox) in patients with advanced carcinoma expressing the Lewis(Y) antigen. Proc Am Soc Clin Oncol 14:A1532, 1995 (abstr)
8. Slichenmyer WJ, Saleh MN, Bookman MA, et al: Phase I studies of BR96 doxorubicin in patients with advanced solid tumors that express the Lewis Y antigen. Anti-Cancer Treatment, Sixth International Congress, 1996, pp 95:6-9, (abstr)
9. Gehan E: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961
10. Trail PA, Onetto N, Lasch S, et al: Tumor penetration and functional activity of BMS-182248 following administration in a phase I clinical trial. Proc Am Assoc Cancer Res 36:A2974, 1995 (abstr)
11. Saleh ML, LoBuglio AF, Trail PA: Monoclonal antibody-based immunoconjugate therapy for cancer: Studies with BR96-doxorubicin, in Grossbard J (ed): Monoclonal Antibody-Based Therapy of Cancer. New York, NY, Marcel Dekker, 1998, pp 397-416